What is HC Wainwright’s Forecast for RNAC FY2027 Earnings?

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Equities research analysts at HC Wainwright issued their FY2027 EPS estimates for Cartesian Therapeutics in a research note issued to investors on Tuesday, May 12th. HC Wainwright analyst M. Kapoor forecasts that the company will post earnings per share of ($3.79) for the year. HC Wainwright has a “Buy” rating and a $25.00 price objective on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($3.93) per share.

A number of other brokerages have also recently issued reports on RNAC. Weiss Ratings reissued a “sell (e+)” rating on shares of Cartesian Therapeutics in a research note on Friday, March 27th. Cantor Fitzgerald raised shares of Cartesian Therapeutics from a “neutral” rating to an “overweight” rating and set a $16.00 target price on the stock in a research note on Monday, March 9th. BTIG Research reaffirmed a “buy” rating on shares of Cartesian Therapeutics in a research note on Monday, March 9th. Wedbush reaffirmed an “outperform” rating and set a $38.00 target price on shares of Cartesian Therapeutics in a research note on Friday, May 1st. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $42.00 target price on shares of Cartesian Therapeutics in a research note on Monday, March 9th. Five analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Cartesian Therapeutics Price Performance

Shares of NASDAQ:RNAC opened at $8.70 on Wednesday. The company’s 50 day simple moving average is $6.95 and its 200 day simple moving average is $7.22. The stock has a market capitalization of $255.61 million, a price-to-earnings ratio of -1.47 and a beta of 0.58. Cartesian Therapeutics has a 1 year low of $5.60 and a 1 year high of $15.57.

Cartesian Therapeutics (NASDAQ:RNAC) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.62). The firm had revenue of $0.08 million for the quarter, compared to the consensus estimate of $0.22 million.

Hedge Funds Weigh In On Cartesian Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Privium Fund Management B.V. acquired a new position in Cartesian Therapeutics in the fourth quarter valued at $1,244,000. R Squared Ltd acquired a new position in Cartesian Therapeutics in the fourth quarter valued at $74,000. GSA Capital Partners LLP lifted its holdings in Cartesian Therapeutics by 106.9% in the third quarter. GSA Capital Partners LLP now owns 86,095 shares of the company’s stock valued at $880,000 after buying an additional 44,493 shares during the period. AlphaQuest LLC lifted its holdings in Cartesian Therapeutics by 64.6% in the third quarter. AlphaQuest LLC now owns 6,924 shares of the company’s stock valued at $71,000 after buying an additional 2,717 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Cartesian Therapeutics by 27.5% in the first quarter. Rhumbline Advisers now owns 13,006 shares of the company’s stock valued at $171,000 after buying an additional 2,805 shares during the period. Institutional investors and hedge funds own 86.95% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, trading on NASDAQ under the symbol RNAC, is a clinical‐stage biotechnology company specializing in the development of messenger RNA (mRNA)-based therapeutics. The company leverages a proprietary RNA delivery platform to induce the production of therapeutic proteins within patients, aiming to address a range of diseases through in vivo expression of disease-modifying agents. Cartesian’s technology is designed to optimize mRNA stability, translation efficiency and targeted delivery, with potential applications spanning oncology, autoimmune disorders and rare genetic conditions.

At the core of Cartesian’s approach is a synthetic mRNA platform that incorporates proprietary lipid nanoparticle (LNP) formulations.